Keywords: دفع گلوکز ادرار; SGLT2 inhibitor; Hyperglycemia; Hyperinsulinemia; Urinary glucose excretion; Diabetes
مقالات ISI دفع گلوکز ادرار (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دفع گلوکز ادرار; SGLT2 inhibitor; Hyperglycemia; Hyperinsulinemia; Urinary glucose excretion; Diabetes
Keywords: دفع گلوکز ادرار; AE; adverse event; AUC; area under the concentration-time curve; BMI; body mass index; C150; canagliflozin 150Â mg; C300; canagliflozin 300Â mg; CI; confidence interval; CRC; clinical research center; CV; coefficient of variation; FPG; fasting plasma gluc
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
Keywords: دفع گلوکز ادرار; Ipragliflozin; SGLT2; Hyperglycemia; Urinary glucose excretion; Obesity; Diabetes;
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Keywords: دفع گلوکز ادرار; ALT; Alanine aminotransferase; AMPK; AMP-activated protein kinase; AST; aspartate aminotransferase; ATMs; adipose tissue macrophages; BAT; brown adipose tissue; CT; computed tomographic; DIO; high-fat-diet-induced obese; EGP; endogenous glucose production
Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus
Keywords: دفع گلوکز ادرار; Chinese patients; empagliflozin; fasting plasma glucose; pharmacokinetics; urinary glucose excretion;
LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion
Keywords: دفع گلوکز ادرار; fasting plasma glucose; LX4211; pharmacokinetics; postprandial glucose; renal impairment; SGLT1; SGLT2; urinary glucose excretion;
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Keywords: دفع گلوکز ادرار; Ipragliflozin; Sodium–glucose cotransporter 2; Urinary glucose excretion; Diabetes; Obesity; High-fat diet
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2
Keywords: دفع گلوکز ادرار; Dapagliflozin; Occupational exposure limit; Pharmacokinetics; SGLT2 inhibitors; Urinary glucose excretion;
Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors
Keywords: دفع گلوکز ادرار; Synthesis; C-Glucoside; SGLT2 inhibitor; Urinary glucose excretion; Cyclohexane-bearing
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Keywords: دفع گلوکز ادرار; Ipragliflozin; SGLT2; Hyperglycemia; Urinary glucose excretion; Diabetes
Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects
Keywords: دفع گلوکز ادرار; Diabetes; GLP-1; SGLT1; SGLT2; PYY; urinary glucose excretion;
Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes
Keywords: دفع گلوکز ادرار; adult; diabetes; dipeptidyl peptidase-4; GIP; GLP-1; glucose; glycemic control; human; insulin; PYY; SGLT1; SGLT2; sitagliptin; urinary glucose excretion;
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
Keywords: دفع گلوکز ادرار; Sergliflozin etabonate; SGLT2 inhibitor; Urinary glucose excretion; Glycemic control; Streptozotocin-induced diabetic rats; Zucker fatty rat